Therapeutic efficacy of Trelagliptin

1.Trial design

For patients with type 2 diabetes mellitus with poor glycemic control after the implementation of dietary therapy and exercise therapy, 100mg of Trelagliptin was orally administered once a week for 12 weeks.

2.Test results

The adjusted mean (standard error) of the change in glycosylated hemoglobin (NGSP value) at the end of the treatment period compared with before medication was -0.54 (0.068)% in the 100mg troxagliptin group and 0.35 (0.068)% in the placebo group, and the glycosylated hemoglobin in the troxagliptin group was significantly reduced compared with the placebo group. In addition, the mean (standard deviation) of glycosylated hemoglobin (NGSP values) before administration was 8.41 (0.97)% in the troxagliptin group and 8.15 (0.95)% in the placebo group. The frequency of side effects in the Trelagliptin group was 9.1%, and no hypoglycemic side effects occurred.